Physician profile
Khashayar Sehhat
NPI 1013942994
$3,047.26
in general payments reported to CMS, 2019-2025
19 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $276 · 2021: $603 · 2022: $314 · 2023: $299 · 2024: $173 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $502.36 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $410.85 | 2019-2021 | |
| Bridgebio Pharma, INC. | $308.85 | 2025 | Attruby |
| Medtronic, INC. | $257.63 | 2021-2023 | |
| Novo Nordisk INC | $244.29 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $201.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $172.24 | 2023 | Xarelto |
| Cardiovascular Systems INC. | $151.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $150.28 | 2022-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $134.05 | 2019-2022 | |
| Pfizer INC. | $125.08 | 2019-2025 | |
| Abbott Laboratories | $99.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.65 | 2021-2025 | Jardiance |
| Edwards Lifesciences Corporation | $64.00 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $38.61 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.12 | 2019 | |
| Preventice Services, LLC | $28.77 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $25.00 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $23.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khashayar Sehhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.